Pembrolizumab (Keytruda, MSD) 'in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage 3 – 4A locally advanced cervical cancer in adults who have not received prior definitive therapy'.
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
Pembrolizumab costs £2,630 per 100‑mg vial (excluding VAT; BNF online accessed January 2026), or around £91,000 for a year of treatment.
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on MSD's webpage on responsibility.